Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akseli Hemminki

Showing results (11-20 of 280) with videos related to

Pageof 28
Sort By:
Annals of Medicine|July 9, 2008
Cancer, stem cells, and oncolytic virusesCamilla Ribacka, Sari Pesonen, Akseli Hemminki
Expert Opinion on Biological Therapy|August 31, 2007
Gene therapy of gynaecological diseasesAnna Kanerva, Mari Raki, Akseli Hemminki
Molecular Pharmaceutics|December 4, 2010
Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical dataSari Pesonen, Lotta Kangasniemi, Akseli Hemminki
Expert Opinion on Biological Therapy|February 23, 2011
Oncolytic vaccinia virus for the treatment of cancerKilian Guse, Vincenzo Cerullo, Akseli Hemminki
Gynecologic Oncology|July 28, 2006
Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinomaWenfang Shi, Akseli Hemminki, Jeffrey S Bartlett
Expert Opinion on Biological Therapy|March 26, 2019
Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune systemVictor Cervera-Carrascon, Riikka Havunen, Akseli Hemminki
Oncoimmunology|November 20, 2012
Oncolytic adenoviruses: A potent form of tumor immunovirotherapyVincenzo Cerullo, Markus Vähä-Koskela, Akseli Hemminki
Methods in Enzymology|March 4, 2020
Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibitionJoão Manuel Santos, Riikka Havunen, Akseli Hemminki
Cancer Medicine|August 14, 2023
Conditional survival in breast cancer up to 10 years in the Nordic countriesFrantisek Zitricky, Asta Försti, Akseli Hemminki, et al.
International Journal of Oncology|November 14, 2002
Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review)Gerd J Bauerschmitz, Shannon D Barker, Akseli Hemminki
Pageof 28

Showing results (11-20 of 280) with videos related to

Sort By:
Pageof 28
Annals of Medicine|July 9, 2008
Cancer, stem cells, and oncolytic virusesCamilla Ribacka, Sari Pesonen, Akseli Hemminki
Expert Opinion on Biological Therapy|August 31, 2007
Gene therapy of gynaecological diseasesAnna Kanerva, Mari Raki, Akseli Hemminki
Molecular Pharmaceutics|December 4, 2010
Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical dataSari Pesonen, Lotta Kangasniemi, Akseli Hemminki
Expert Opinion on Biological Therapy|February 23, 2011
Oncolytic vaccinia virus for the treatment of cancerKilian Guse, Vincenzo Cerullo, Akseli Hemminki
Gynecologic Oncology|July 28, 2006
Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinomaWenfang Shi, Akseli Hemminki, Jeffrey S Bartlett
Expert Opinion on Biological Therapy|March 26, 2019
Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune systemVictor Cervera-Carrascon, Riikka Havunen, Akseli Hemminki
Oncoimmunology|November 20, 2012
Oncolytic adenoviruses: A potent form of tumor immunovirotherapyVincenzo Cerullo, Markus Vähä-Koskela, Akseli Hemminki
Methods in Enzymology|March 4, 2020
Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibitionJoão Manuel Santos, Riikka Havunen, Akseli Hemminki
Cancer Medicine|August 14, 2023
Conditional survival in breast cancer up to 10 years in the Nordic countriesFrantisek Zitricky, Asta Försti, Akseli Hemminki, et al.
International Journal of Oncology|November 14, 2002
Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review)Gerd J Bauerschmitz, Shannon D Barker, Akseli Hemminki
Pageof 28